Borbone, Eleonora (2009) EVALUATION OF HISTONE DEACETYLASE INHIBITOR EFFECTS ON THYROID CANCER. [Tesi di dottorato] (Inedito)

[img]
Anteprima
PDF
Borbone_Eleonora.pdf

Download (21MB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: EVALUATION OF HISTONE DEACETYLASE INHIBITOR EFFECTS ON THYROID CANCER
Autori:
AutoreEmail
Borbone, Eleonoraelly_norab@yahoo.it
Data: 31 Marzo 2009
Numero di pagine: 89
Istituzione: Università degli Studi di Napoli Federico II
Istituzioni (extra): CEINGE  Biotecnologie Avanzate
Dipartimento: CEINGE Biotecnologie avanzate
Scuola di dottorato: SEMM – European School of Molecular Medicine
Dottorato: PhD in Molecular Medicine (Molecular Oncology or Human Genetics)
Ciclo di dottorato: 20
Coordinatore del Corso di dottorato:
nomeemail
Salvatore, Francesco[non definito]
Tutor:
nomeemail
Fusco, Alfredoafusco@napoli.com
Simeone, Antonio[non definito]
Gronemeyer, Hinrich[non definito]
Data: 31 Marzo 2009
Numero di pagine: 89
Parole chiave: HDAC, thyroid, cancer
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/11 - Biologia molecolare
Area 06 - Scienze mediche > MED/06 - Oncologia medica
Informazioni aggiuntive: Ciclo II/XX, Curriculum Molecular Oncology
Depositato il: 16 Nov 2009 14:59
Ultima modifica: 14 Gen 2015 12:26
URI: http://www.fedoa.unina.it/id/eprint/3402
DOI: 10.6092/UNINA/FEDOA/3402

Abstract

Abstract Histone deacetylases (HDACs) play a crucial role in the proper regulation of cellular functions through their connection with chromatin and transcriptional regulation. Alterations in HDAC activity have been reported in several types of cancer encouraging development of HDAC inhibitors (HDACis) for cancer treatment. The antitumor activity of HDACi has been demonstrated, in clinical trials, in both solid and non solid neoplasias at doses well tolerated by patients. However, the molecular basis for their tumor selectivity is unknown. Anaplastic thyroid carcinoma (ATC) is one of the most aggressive malignancies, having a poor prognosis and being refractory to conventional chemo- and radiotherapy. To the aim to find an innovative therapy for the treatment of ATCs, we studied the effects of two potent HDACis, SAHA and MS-275, on rat thyroid cell lines transformed by the v-ras-Ki oncogene which is frequently mutated in ATCs. We show that: i) HDAC 1 and HDAC 2 are overexpressed in anaplastic thyroid carcinomas compared to normal thyroid; ii) SAHA and MS-275 induce apoptosis selectively in completely transformed rat thyroid cells; iii) TNF-related apoptosis-inducing ligand (TRAIL) is the main mediator of cell death induced by SAHA; iv) SAHA stabilize TRAIL protein by affecting its proteasome-mediated degradation.

Downloads

Downloads per month over past year

Actions (login required)

Modifica documento Modifica documento